Marshall Wace, LLP Genmab A/S Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Genmab A/S stock. As of the latest transaction made, Marshall Wace, LLP holds 2,181,510 shares of GMAB stock, worth $49.8 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
2,181,510
Previous 1,122,296
94.38%
Holding current value
$49.8 Million
Previous $23.4 Million
82.36%
% of portfolio
0.06%
Previous 0.03%
Shares
14 transactions
Others Institutions Holding GMAB
# of Institutions
248Shares Held
66.2MCall Options Held
729KPut Options Held
398K-
Alliancebernstein L.P. New York, NY14.7MShares$336 Million0.11% of portfolio
-
Orbis Allan Gray LTD Hamilton, D05.71MShares$130 Million0.8% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$116 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.43MShares$101 Million0.02% of portfolio
-
Harding Loevner LP Bridgewater, NJ2.88MShares$65.8 Million0.45% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $15B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...